Citi analyst Patrick Donnelly downgraded Illumina (ILMN) to Neutral from Buy with a price target of $165, down from $190. The firm sees less clarity on the conpany’s growth ramp given more pronounced pricing headwinds in the first half of 2025 from the NovaSeq X ramp and believes the cost out story is appropriately priced into the multiple.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina enters licensing agreement with Lonza
- Illumina releasing expanded version of TruSight Oncology portfolio
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina resumed with an Equal Weight at Morgan Stanley